Ularitide: a natriuretic peptide candidate for the treatment of acutely decompensated heart failure.
Treatment for acutely decompensated heart failure (ADHF) has not changed much in the last two decades. Currently available therapies have variable efficacy and can be associated with adverse outcomes. Natriuretic peptides properties include diuresis, natriuresis, vasorelaxation, inhibition of renin-angiotensin-aldosterone system, and are thus chosen in the treatment of ADHF. Two forms of natriuretic peptides are currently available for the treatment of ADHF. Urodilatin (INN: ularitide) represents another member of the natriuretic peptide family with a unique molecular structure that may provide distinct benefits in the treatment of ADHF. Early clinical exploratory and Phase II studies have demonstrated that ularitide has potential cardiovascular and renal benefits. Ularitide is currently being tested in the Phase III TRUE-AHF clinical study. TRUE-AHF has features that may be different when compared with other recent outcome studies in ADHF. These distinct differences aim to maximize clinical effects and minimize potential adverse events of ularitide. However, whether this rationale translates into a better outcome needs to be awaited.
Division of Cardiology, The Ohio State University, 473 W 12th Ave, Suite 200 DHLRI, Columbus, OH 43210, USA.
Sitaramesh
S
Emani
Cardiorentis Ltd, Steinhauserstrasse 74, Zug 6300, Switzerland.
Markus
M
Meyer
Department of Internal Medicine, University of Cincinnati, Medical Sciences Building, 231 Albert Sabin Way #6065, Cincinnati, OH 45267, USA.
Denada
D
Palm
Cardiorentis Ltd, Steinhauserstrasse 74, Zug 6300, Switzerland.
Johannes
J
Holzmeister
Division of Cardiology, The Ohio State University, 473 W 12th Ave, Suite 200 DHLRI, Columbus, OH 43210, USA.
Garrie J
GJ
Haas
D000208:Acute Disease; D009320:Atrial Natriuretic Factor / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D010446:Peptide Fragments / Q000627:therapeutic use; D016896:Treatment Outcome
D004232:Diuretics; D010446:Peptide Fragments; C056452:Ularitide; D009320:Atrial Natriuretic Factor
acutely decompensated heart failure; natriuretic peptide; ularitide; urodilatin